<DOC>
	<DOCNO>NCT01262638</DOCNO>
	<brief_summary>This Phase 2 proof-of-concept study ass lipid regulate efficacy safety ETC-1002 subject hypercholesterolemia either normal elevate triglyceride .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety ETC-1002 Subjects With Elevated Blood Cholesterol Either Normal Elevated Triglycerides</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Major Provision write informed consent prior studyspecific procedure Fasting LDLC 130 220 mg/dL follow washout lipid regulating medication supplement Fasting triglyceride &lt; 400 mg/dL follow washout lipid regulating medication supplement BMI 18 35 mg/kg2 Major Clinically significant cardiovascular disease , diabetes uncontrolled hypertension Females child bear potential ( i.e. , female surgically sterile postmenopausal )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>